Posts by: Alice Melão

Alice Melão

September 21, 2018September 21, 2018

Ocrevus Climbing as First-line DMT for RRMS Among Neurologists Surveyed in Spherix Report

News

Eighteen months after its entrance into the U.S. market, Genentech’s Ocrevus (ocrelizumab) has become the monoclonal antibody of choice to treat patients with multiple sclerosis (MS), according ... Read more

September 5, 2018September 5, 2018

Mavenclad Approved to Treat Highly Active Relapsing MS Patients in Ireland

News

Adults in Ireland with highly active relapsing multiple sclerosis (MS) now can be treated with Mavenclad (cladribine tablets, 10 mg), the first short-course oral treatment approved ... Read more

August 8, 2018August 8, 2018

Quanterix’s Simoa Assay May Make Neurofilament Light Chain Useful Blood Biomarker of MS and Its Likely Progression

News

Quanterix’s ultra-sensitive Simoa assay has the potential to open new uses for the brain biomarker known as neurofilament light chain, including the possibility to detect early ... Read more

August 2, 2018August 7, 2018

Potential B-cell Targeting Oral MS Treatment, PRN2246, Shows Ability to Reach Brain in Phase 1 Study

News

Results from a first-in-human study assessing the safety and early activity of PRN2246 confirmed that the oral compound can reach into the brain and spinal cord. This ... Read more

July 31, 2018July 31, 2018

FDA to Review EMD Serono’s New Request for Approval of Cladribine for Treating Relapsing MS

News

Seven years after it first denied the request, the U.S. Food and Drug Administration accepted for review EMD Serono’s resubmitted New Drug Application (NDA) for cladribine ... Read more

July 27, 2018July 30, 2018

Oral DMTs Still Common 1st Therapy for New MS Patients but Ocrevus Having Impact, Market Report Says

News

Oral disease-modifying therapies (DMTs) are the most common first choice of treatment for people newly diagnosed with multiple sclerosis (MS) in the United States, an analysis ... Read more

July 24, 2018July 25, 2018

Enzyme Key to Myelin Renewal and Nerve Cell Health Possibly Identified in Study

News

A better understanding of the processes behind a continual and healthy renewal of myelin — the fatty, protective substance wrapping nerve cell fibers — may now ... Read more

July 17, 2018July 17, 2018

Progressive MS Patients with Considerable Disability Ably Treated with Cladribine, UK Case Study Reports

News

Cladridine may be effective in preventing disability progression and reducing damage to nerve cells in people with progressive forms of multiple sclerosis (MS), researchers suggest based on a ... Read more

July 13, 2018July 17, 2018

Common Anti-Parasitic Agent Eases Motor Symptoms, Aids Remyelination in MS Mouse Model

News

A common anti-parasitic agent showed a potential to prevent inflammation and to promote nerve cell recovery — remyelination — in a mouse model of multiple sclerosis ... Read more

July 3, 2018

No Risk of MS Found in GlaxoSmithKline Vaccine for Swine Flu, Canadian Study Says

News

Protecting the public against an outbreak like the swine flu using GlaxoSmithKline‘s vaccine Arepanrix — or a similar vaccine with an AS03 adjuvant delivery system — does not increase a ... Read more

June 28, 2018June 28, 2018

Probe That Acts as PET Scan Tracer May Give Glimpse into Gene Therapy’s Effects on Brain

News

A radioactive probe that might enable imaging tools to effectively monitor what a gene therapy is doing in the brain — important in treating diseases like ... Read more

June 21, 2018June 21, 2018

#EAN2018 – Pupil Response to Light Linked to RRMS Duration and Severity in Study

News

Measuring the response of the pupil to light stimulating the eye is a non-invasive and easy way to assess multiple sclerosis (MS) severity and progression, researchers ... Read more

June 20, 2018June 27, 2018

#EAN2018 – New Guidelines for MS Treatment in Europe Set by EAN, ECTRIMS

News

New treatment guidelines for multiple sclerosis (MS) patients in Europe were set in place through an initiative undertaken by the European Academy of Neurology (EAN) and ... Read more

June 19, 2018June 19, 2018

#EAN2018 – Ocrevus Lowers Relapse Rates Over Long Term and Better Than Rebif Does, Data Show

News

Long-term treatment with Ocrevus (ocrelizumab)  — as well as switching from Rebif (interferon beta-1a) to Ocrevus — leads to a significant and sustained reduction in disease ... Read more

June 15, 2018June 21, 2018

#EAN2018 – Ocrevus May Delay Progression to Wheelchair by Up to 7 Years, New Analysis of PPMS Patient Data Shows

News

Treatment with Ocrevus (ocrelizumab) slows disability progression in primary progressive multiple sclerosis (PPMS) in ways that may be of considerable importance to patients — including the ... Read more

June 8, 2018June 8, 2018

Mobility Devices for People Who Have Lower-Limb Paralysis are Flawed, Online Survey Reveals

News

More investment and new technological developments are needed to assist people who have limited mobility because of lower-limb paralysis. That was the major conclusion of an ... Read more

June 7, 2018June 8, 2018

#CMSC2018 – Pharmacist Discusses Advances, Challenges in Cannabinoids Research to Treat MS

News

Several studies have demonstrated the therapeutic potential of cannabis and its derivate products to manage the symptoms of multiple sclerosis (MS) and other neurodegenerative diseases. But ... Read more

June 5, 2018June 5, 2018

#CMSC2018 — Advances Made in Care of Children with MS, but Challenges Remain, Expert Says

News

While the treatment and care of children and teenagers with multiple sclerosis (MS) has seen many developments in recent years, there are still many challenges to ... Read more

May 25, 2018May 30, 2018

Limited Use of Large Muscles Affects Health of Nerve Cell-producing Stem Cells in Brain, Mouse Study Finds

News

Lesser time spent exercising and using large muscles can result in serious alterations in the metabolism of brain stem cells and their ability to generate new nerve ... Read more

May 15, 2018May 15, 2018

Gilenya Approved by FDA as First DMT for Children, Ages 10 and Older, with Relapsing MS

News

Gilenya (fingolimod) has become the first disease-modifying therapy approved by the U.S. Food and Drug Administration (FDA) to treat children and adolescents with relapsing forms of ... Read more

May 8, 2018May 8, 2018

Rituximab Seen to Ably and Safely Treat Refractory RRMS Patients in French Study

News

An approved lymphoma treatment, rituximab was found to be effective and safe for relapsing-remitting multiple sclerosis (RRMS) patients whose active disease has failed to respond to immunosuppressive ... Read more

May 3, 2018May 3, 2018

Mavenclad Effective in Treating Highly Active MS, New CLARITY Analysis Shows

News

An additional analysis of data from the CLARITY study confirmed the long-term benefits of treatment with Mavenclad (cladribine tablets) for patients with highly active relapsing forms ... Read more

May 2, 2018May 16, 2018

#AAN2018 — Lemtrada Sustains Long-Term Benefits for RRMS Patients, TOPAZ Study Shows

Lemtrada, News

Lemtrada (alemtuzumab) can sustain reduced activity and prevent progression of relapsing-remitting multiple sclerosis (RRMS) for more than seven years, clinical data from the CARE-MS extension trial ... Read more

April 27, 2018May 1, 2018

#AAN2018 – Stem Cell Transplant is Effective Treatment for ‘Aggressive’ MS, Study Shows

News

Autologous hematopoietic stem cell transplantation, also known as aHSCT, has been shown to be safe and highly effective to treat patients with “aggressive” multiple sclerosis. Tested ... Read more

April 26, 2018April 30, 2018

#AAN2018 – MS Progresses Quickly in African-Americans and May Warrant Aggressive Treatment

News

Multiple sclerosis in African-Americans progresses much faster than in Caucasian patients, new research reports, suggesting that blacks would benefit from a more aggressive treatment approach. Led ... Read more

April 25, 2018

#AAN2018 – Review of Phase 3 Trial Data Supports Gilenya as Treatment for Pediatric MS

News

An additional analysis of data collected during the Phase 3 PARADIGMS trial found Gilenya (fingolimod) can prevent the progression of disability and control multiple sclerosis (MS) activity in ... Read more

April 24, 2018April 24, 2018

#AAN2018 – Celgene to Present Latest Data on Ozanimod’s Safety and Effectiveness

News

Celgene’s oral treatment candidate ozanimod can effectively reduce relapse rates in multiple sclerosis (MS) patients with mild to moderate disability, results of two Phase 3 trials ... Read more

April 23, 2018April 23, 2018

#AAN2018 – Neurofilament Light Blood Levels Can Help Define Disease Activity in RRMS, Study Shows

News

Analysis of a potential blood biomarker linked to brain cell damage can help define disease activity in patients with relapsing-remitting multiple sclerosis (RRMS). Results of a ... Read more

April 18, 2018April 18, 2018

#AAN2018 – Levels of Protein Derived from Brain Cell Damage Can Mirror Severity of MS, Study Finds

News

Levels of a protein stemming from brain cell damage can mirror the severity and symptoms of multiple sclerosis, an analysis of combined data from three trials ... Read more

April 18, 2018April 18, 2018

#AAN2018 — Early Treatment Delays MS Disease Progression But Does Not Affect Death Rate, Study Suggests

News

Beginning treatment early with disease-modifying therapies is the most effective approach to prevent multiple sclerosis (MS) progression in patients, a large-scale study suggests. Data from the ... Read more

April 17, 2018April 17, 2018

#AAN2018 – Siponimod Reduces Disease Activity Biomarker in SPMS Patients

News

Novartis‘ siponimod (BAF312) can reduce blood levels of a biomarker of nerve cell damage in patients with secondary progressive multiple sclerosis (SPMS), a Phase 3 clinical ... Read more

April 16, 2018April 16, 2018

SPMS Patients Have More Cognitive Decline Than Those with RRMS, Study Reports

News

People with secondary progressive multiple sclerosis (SPMS) have more cognitive decline than those with relapsing-remitting MS (RRMS), according to a Greek study. The finding confirmed a ... Read more

April 11, 2018April 11, 2018

Mapi Pharma, Mylan Partner to Develop Once-monthly Glatiramer Formulation

News

Mylan and Mapi Pharma will jointly develop and commercialize Glatiramer Acetate (GA) Depot, an investigative, long-lasting formulation of the commonly used multiple sclerosis (MS) therapy Copaxone (marketed by Teva ... Read more

April 11, 2018April 11, 2018

Mavenclad Approved by United Arab Emirates to Treat Highly Active Relapsing MS

News

The United Arab Emirates is the first country in the Middle East and Africa to approve Mavenclad (cladribine tablets) as a treatment for patients with highly ... Read more

April 4, 2018April 4, 2018

Online Therapy Program Called Elevida Seen to Help Patients to Manage Fatigue in Clinical Study

News

An interactive, psychotherapy-based online program known as Elevida can effectively reduce fatigue in patients with multiple sclerosis (MS), results of a clinical study show. In their ... Read more

March 27, 2018March 27, 2018

Siponimod Reduces Risk of SPMS Patients’ Disability Worsening, Phase 3 Trial Shows

News

Siponimod (BAF312) reduces the risk of disability progression in patients with secondary progressive multiple sclerosis (SPMS), a Phase 3 clinical trial shows. An article about the Novartis therapy’s trial ... Read more

March 26, 2018March 26, 2018

Canadian Study Links Psychiatric Disorders and Physical Disability in Women with MS

News

Depression, anxiety and other mood disorders contribute to physical disability in women with multiples sclerosis, according to a Canadian study that confirmed the results of previous ... Read more

March 14, 2018March 21, 2018

National MS Society to Award $433,800 to Support 10 Pilot Research Projects

News

The National Multiple Sclerosis Society will award $433,800 to 10 high-risk pilot studies that will quickly evaluate new strategies and interventions and enhance knowledge about multiple ... Read more

March 13, 2018March 13, 2018

Genetically Engineered Cells Have Potential to Restore Neuron’s Myelin Sheath, Study Shows

News

Genetically modified human umbilical cord blood cells can help nerve cells recover the myelin layer necessary for normal functioning, researchers found in a preclinical study. This ... Read more

March 2, 2018March 5, 2018

FDA Wants More Information on Celgene’s MS Therapy Ozanimod Before Starting Its Review

News

The U.S. Food and Drug Administration has asked Celgene to add more information to its New Drug Application for ozanimod as a treatment for relapsing forms of ... Read more